For research use only. Not for therapeutic Use.
Moricizine Hydrochloride (EN 313) is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period[1].
Catalog Number | R045871 |
CAS Number | 29560-58-5 |
Synonyms | ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate;hydrochloride |
Molecular Formula | C22H26ClN3O4S |
Purity | ≥95% |
InChI | InChI=1S/C22H25N3O4S.ClH/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24;/h3-8,15H,2,9-14H2,1H3,(H,23,27);1H |
InChIKey | GAQAKFHSULJNAK-UHFFFAOYSA-N |
SMILES | CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4.Cl |
Reference | [1]. Bigger JT Jr. Cardiac electrophysiologic effects of moricizine hydrochloride. Am J Cardiol. 1990 Feb 20;65(8):15D-20D; discussion 68D-71D. |